Bone marrow transplantation and cord blood transplantation in children;Transplante de medula óssea e transplante de sangue de cordão umbilical em pediatria

Jornal de Pediatria

Volumn 77, Issue 5, 2001, Pages 345-360

  De Castro Jr , Cláudio Galvão ^a,e   Gregianin, Lauro José ^a,b   Brunetto, Algemir Lunardi ^a,b,c,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e Servico de Oncol Pediatrica   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0242648145     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/jped.275     Document Type: Review

References (100)

1. Armitage JO. Bone Marrow Transplantation. N Engl J Med 1994; 330: 827-38.
2. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow; case report. Ann Intern Med 1939: 13:357-67.
3. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea-pigs by bone marrow injections. J Natl Cancer Inst 1951; 12:197-201.
4. Thomas ED, Collins JA, Hernan Jr EC, Ferrebee JW. Marrow transplantations in lethally irradiated dogs given methotrexate. Blood 1962; 19: 217-28.
5. Epstein RB, Bryant J, Thomas ED. Cytogenetic demonstration of permanent tolerance in adult outbred dogs. Transplantation 1967; 5: 267-72.
6. Dausset J. Iso-leuco-anticorps. Acta Haematol 1958;20:156-66.
7. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968; 2:1364-66.
8. Gatti RA, Meuwissen HJ, Allen HD. Immunological reconstitution of sex-linked immunological deficiency. Lancet 1968; 2:1366-9.
9. Good RA, Meuwissen HF, Hong R, Gatti RA. Successful marrow transplantation for correction of immunological deficit in lymphopenic agammaglobulinemia and treatment of immunologically induced pancytopenia. Exp Hematol 1969; 19:4-10.
10. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832-43.
11. Thomas ED. The evolution of the scientific foundation of marrow transplantation based on human studies In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Massachusetts: Blackwell Scientific Publications; 1994. p. 12-5.
12. Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978: 52:85-95.
13. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970; 36:507-15.
14. Bortin MM, Buckner CD. Major complications of marrow harvesting for transplantation. Exp Hematol 1983: 916-21.
15. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, et al. Marrow harvesting from normal donors. Blood 1984. 64:630-4.
16. Horowitz MM, Keating A. IBMTR/ABMTR Newsletter 2000; 7: 3-10.
17. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529-32.
18. Reiffers J, Bernard P, David B, Pezzutto A, Hunstein W, Fliedner TM. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312-5.
19. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999; 39: 555-60.
20. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, et al. Three to 6-year follow-up of normal donors who received recombinant human granulocyte colony stimulating factor. Bone Marrow Transplant 2000; 26:1291-8.
21. Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from a HLA-identical sibling. N Engl J Med 1989; 321:1174-8.
22. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565-77.
23. Storb R. Bone marrow transplantation for aplastic anemia. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994.p.583-94.
24. Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, et al. Bone marrow transplantation for Fanconi Anemia. Blood 1995; 86:2856-62.
25. O'Reilly R, Friedrich W, Small TN. Transplantation approaches for several combined immunodeficiency diseases, Wiskott-Aldrich syndrome, and other lethal genetic, combined immunodeficiency disorders. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994; p.849-73.
26. Weinberg K. White blood cell disorders. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994.p.894-901.
27. Coccia PF. Bone marrow transplantation for osteopetrosis. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994.p.874-82.
28. Krivit W, Shapiro EG. Bone marrow transplantation for storage diseases. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994. p.883-93.
29. Giardini C, Lucarelli G. Bone marrow transplantation for betathalassemia. Hematol Oncol Clin North Am 1999; 13:1059-64.
30. Piatt OS. Bone marrow transplantation in sickle cell anemia - the dilemma of choice. N Engl J Med 1996; 335:426-8.
31. Copelan EA, Penza SL, Theil KS, Elder PJ, Bechtel TP, Tighe MB, et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML, following BuCY. Bone Marrow Transplant 2000; 26: 1037-43.
32. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309:1347.
33. 3rd ed. Philadelphia: Lippincott & Wilkins; 2000. p.667-89.
34. Brochstein JÁ, Kernan NA, Groshan S, Cirrincione C, Shank B, Emanuel D, et al. Allogeneic marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987; 317: 1618-24.
35. Dopfer R, Henze G, Bender-Gotze C, Ebell W, Ehninger G, Friedrich W, et al. Allogeneic marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the cooperative BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 1991; 78: 2780-4.
36. Appelbaum FR. Allogeneic bone marrow transplantation for myelodysplastic and myeloproliferative disorders. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994. p.629-39.
37. Sekhar M, Prentice HG, Popat U, Anderson D, Janmohammed R, Roberts I, Britt RP. Idiopathic myelofibrosis in children. Br J Haematol 1996; 93:394-97.
38. Hale GA, Tong X, Benaim E, Cunningham JM, Heslop HE, Horwiz EM, et al. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant 2001; 27:155-62.
39. Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernandez JM, et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000; 25:31-4.
40. Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90:2921-30.
41. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165-73.
42. Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000; 34:328-37.
43. Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, et al. High-dose melphalan, etoposide and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology Study. J Clin Oncol 1998; 16: 3295-301.
44. Morris MJ, Bosl GJ. High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999). Int J Cancer 1999; 83:834-38.
45. Papadakis V, Dunkel IJ, Cramer LD, Kramer E, Papadopoulos E, Goldman S, et al. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone Marrow Transplant 2000; 26:153-60.
46. Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 1979; 148: 871-74.
47. Dulley FL. Bussulfano e ciclofosfamida como condicionamento para o transplante de medula óssea da anemia aplástica grave [tese]. São Paulo: Universidade de São Paulo; 2000.
48. Diaz MA, Vicent MG, Madero L. High-dose busulfan/ melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157-9.
49. Storb R, Sanders JE, Pepe M, Anasetti C, Appelbaum FR, Buckner CD, et al. Graft versus host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Blood 1991; 78: 1144-9.
50. Coccia PF, Stranjord SE, Warkentin OI, Cheung NK, Gordon EM, Novak LJ, et al. High dose cytosine arabinoside and fractionated total body irradiation: an improved preparative regimen for children with acute lymphoblastic leukemia in remission. Blood 1988; 71: 888.
51. Sniecinsky I. Management of ABO incompatibility in allogeneic bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Massachusetts: Blackwell Scientific Publications; 1994.p. 497-503.
52. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-9.
53. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
54. a ed. Philadelphia: Lippincott & Wilkins; 2000. p.331-53.
55. Smith TJ. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in clinical practice: balancing clinical and economic concerns. American Society of Clinical Oncology. Educational Book 1999; 275-80.
56. Sanders JE. Bone marrow transplantation for pediatric malignancies. Pediatric Clinics of North America 1997; 4:1005-20.
57. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA - matched sibling donors. Transplantation 1974; 18: 295-304.
58. Perters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F, et al. Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405-11.
59. Sullivan KM, Agura E, Anaseti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft versus host disease and other late complications of bone marrow transplantation. Semin Hematol 1991 28:250-9.
60. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graf-versus-host disease syndrome in man. A long term clinicopathologic study of 20 Seattle patients. Am J Med 1980: 69:204-17.
61. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-62.
62. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 1990; 6:155-61.
63. Slavin S, Nagler A. New developments in bone marrow transplantation. Curr Opini Oncol 1991;3: 254-91.
64. a ed. Philadelphia: Lippincott & Wilkins; 2000.p. 123-37.
65. Wingard, JR. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 1990; 6:371-83.
66. Buckner CD, Clift, RA, Thomas ED, Hersman J, Sanders JE, Stewart PS, et al. Early infectious complications in allogeneic marrow transplantation recipients with acute leukemia: effects of prophylactic measures. Infection 1983; 11: 243-50.
67. Saboya R. Infecções bacterianas e fúngicas no transplante de medula óssea - análise de 186 pacientes [tese doutorado]. São Paulo: Universidade de São Paulo; 1998.
68. Abi-Sad D, Anaissie EJ, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogeneous candidiasis caused by different Candida species. Clin Infect Dis, 1997; 24:1122-8.
69. a ed. Philadelphia: Lippincott & Wilkins; 2000.p.535-56.
70. Machado CM, Dulley FL, Boas LS, Castelli JB, Macedo MC, Silva RL, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 2000; 26:413-7.
71. Baldwin A, Kingman H, Darville M, Foot AB, Grier D, Cornish JM, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:1233-8.
72. Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, et al. Prophylaxis of herpes infections after bone marrow transplantation by oral acyclovir. Lancet 1983; 2: 706-8.
73. Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K, et al. Chronic cutaneous graft versus host disease in man. Am J Pathol 1978; 91:545-70.
74. a ed. New York: John Wiley and Sons; 1985.p. 1674-6.
75. a ed. Philadelphia: Lippincott & Wilkins; 2000.p.641-8.
76. Szeluga DJ, Stuart RK, Brookmeyer R, Utermohlen V, Santos GW. Nutritional support of marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to enteral feeding program. Cancer Res 1987; 47:3309-16.
77. Cruz LB, Castro Jr CG, Gregianin, LJ, Carvalho GP, Cartagena MI, Brunetto AL. Relato da experiência em nutrição enteral e parenteral em pacientes submetidos a transplante de medula óssea. . Anais do Congresso Brasileiro de Oncologia Pediátrica -Vitória-ES, Brasil. 2000;78. p. 140.
78. a ed. Philadelphia: Lippincott & Wilkins; 2000.p.575-93.
79. Bras G, Jeliffe DB, Stuart KL, Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. Arch Pathol 1954; 57:285-300.
80. McDonald GB, Sharma P, Matheus DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 4:116-22.
81. Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27:627-33.
82. Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996;17:1101-4.
83. Griese M, Raumpf U, Hofmann D, Fuhrer M, Reinhardt D, Bender-Gotze C. Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center. Pediatr Pulmonol 2000; 30: 393-401.
84. a ed. Philadelphia: Lippincott & Wilkins; 2000.p.123-37.
85. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 1996;14:579-85.
86. Patzer L, Ringelmann F, Kentouche K, Fuchs D, Zintl F, Brandis M, et al. Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant 2001;27:319-27.
87. Ilan Y, Nagler A, Zeira E Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant 2000; 26:633-8.
88. Deeg HJ. Delayed complications after bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Massachusetts: Blackwell Scientific Publications; 1994.p.538-44.
89. a ed. Philadelphia: Lippincott & Wilkins; 2000.p.221-42.
90. Souillet G, Rey S, Bertrand Y, Pujol M, Pondarre C, Bourgeot JP, et al. Outcome of unrelated bone marrow donor searches in 174 children resulting in 45 patients transplanted in the HLA-matched and mismatched situation. Bone Marrow Transplant 2000; 26:31-43.
91. Kurtzberg J, Laughlin M, Graham M, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoeitic stem cells for transplantation into unrelated recipients. New Engl J Med 1996; 335: 157-66.
92. a ed. Philadelphia: Lippincott & Wilkins; 2000.p.211-20.
93. M-Reboredo N, Díaz A, Castro A, Villaescusa RG. Collection, processing and cryopreservation of umbilical cord blood for unrelated transplantation. Bone Marrow Transplant 2000; 26:1263-70.
94. Ferreira E, Pasternak J, Bacal N, Guerra JCC, Watanabe FM. Autologous cord blood transplantation. Bone Marrow Transplant 1999; 24:1041.
95. Brunetto AL, Gregianin LJ, Castro Jr. CG, Loss JF, Horta MFO, Pereira JPM, et al. Transplante alogênico com sangue de cordão umbilical de doador não aparentado em pacientes pediátricos. Anais do Congresso Brasileiro de Oncologia Pediátrica - Vitória, ES, Brasil. 2000; 77 p. 136.
96. Barrera M, Pringle B, Sumbler K, Saunders F. Quality of life and behavioral adjustment after pediatric bone marrow transplantation. Bone Marrow Transplant 2000; 26: 427-35.
97. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long term survival and late deaths after allogeneic bone marrow transplantation. New Engl J Med 1999; 341: 14-21.
98. Thomas ED. Does bone marrow transplantation confer a normal life span? New Engl J Med 1999; 341: 50-1.
99. Slavin S, Nagler A. Non-myeloablative conditioning in conjunction with stem cell transplantation - experimental background and clinical potential. Trends in Onco-hematol 1999; 7: 2-4.
100. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl J Med 2000; 343:750-8.